Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous...
Read More Details
Finally We wish PressBee provided you with enough information of ( NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing )
Also on site :
- Numbrix 9 - June 30
- 21-year-old Baloch student becomes another victim of extrajudicial killing by Pakistani forces
- Gold miners killed in pit collapse in war-torn Sudan